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The novel diphenyltin(IV) compound [Ph2(HyFoSc)Sn] (2), where H2HyFoSc (1) is 3-hydroxy-2-formylpyridine semicarbazone,
waspreparedandcharacterizedbyvibrationalandNMR(1H, 13C)spectroscopy.Thestructureof[Ph2(HyFoSc)Sn]wasconﬁrmed
by single-crystal X-ray crystallography. The doubly deprotonated ligand is coordinated to the tin atom through the enolic-oxygen,
the azomethine-nitrogen, and phenolic-oxygen, and so acts as an anionic tridentate ligand with the ONO donors. Two carbon
atoms complete the ﬁvefold coordination at the tin(IV) center. Intermolecular hydrogen bonding, C–H → π,a n dπ → π
interactions combine to stabilize the crystal structure. Compounds 1 and 2 have been evaluated for antiproliferative activity in
vitro against the cells of three human tumor cell lines: MCF-7 (human breast cancer cell line), T24 (bladder cancer cell line), A549
(nonsmall cell lung carcinoma), and a mouse ﬁbroblast L-929 cancer cell line.
1.Introduction
Organotin compounds are of interest in view of their
considerable structural diversity [1]. Increasing interest in
organotin(IV) chemistry has arisen in the last few decades
and is attributed to their signiﬁcantly important biological
properties. Several di- and tri-organotin species have shown
potential as antineoplastic and antituberculosis agents [2–
5]. The binding ability of organotin compounds towards
DNA depends on the coordination number and nature of
groups bonded to the central tin atom. The phosphate group
of DNA-sugar backbones usually acts as an anchoring site
and DNA base-nitrogen binding is extremely eﬀective and
this often results in the stabilization of the octahedrally
coordinated tin center. Recent studies have showed that low
dosesoforganotinscanexhibitantitumoralactivityandhave
suggested a mode of action via a gene-mediated pathway in
thecancercells,openinganewresearchsubareaonorganotin
compounds [6].
Thio- and semicarbazones (TSC) possess a wide range of
bioactivities,andtheirchemistryandpharmacologicalappli-
cations have been extensively investigated. The more signiﬁ-
cant bioactivities of a variety of semicarbazones (antiproto-
zoa, anticonvulsant) and thiosemicarbazones (antibacterial,
antifungal, antitumoral, antiviral) and their metal complexes
have been reviewed together with proposed mechanisms of
action and structure-activity relationships [7, 8] .C a s a se ta l .
[9] have surveyed structural aspects of main group metal
complexes of semicarbazones and thiosemicarbazones. The
survey shows that heterocyclic and nonheterocyclic TSC’s are
very versatile coordination agents with these elements [9].
Following our interest in the chemistry and pharma-
cological properties of thiosemicarbazones [10–17]a n d
towards organotins [18–21], herein, the preparation and2 Bioinorganic Chemistry and Applications
spectroscopic characterization of a novel semicarbazone
and a novel diphenyl organotin compound derived from
the reaction of SnPh2O with 3-hydroxy-2-formylpyridine
semicarbazone H2HyFoSc (1) are described with the ﬁnal
goal of developing new biologically active pharmaceuticals.
The results of the cytotoxic activity of 1,S n P h 2O, and of the
organotin compound (2) against the cells of three human
cancer cell lines: MCF-7 (human breast cancer cell line),
T 2 4( b l a d d e rc a n c e rc e l ll i n e ) ,A 5 4 9( n o n - s m a l lc e l ll u n g
carcinoma), and a mouse ﬁbroblast L-929 cancer cell line are
also reported. To our knowledge, this is the ﬁrst report of
synthesis of 1 and 2.
2. Experimental
2.1.GeneralandInstrumental. Thereagents(Aldrich,Merck,
Sigma) were used as supplied while the solvents were
puriﬁed according to standard procedures. Melting points
were determined in open capillaries and are uncorrected.
Infrared and far-infrared spectra were recorded on a Perkin–
Elmer Spectrum GX FT IR System spectrophotometer using
KBr pellets (4000–400cm−1) and nujol mulls dispersed
between polyethylene disks (400–40cm−1). The 1H, 13C
NMR spectra were recorded on a Bruker AC-300MHz
and on a Varian 600MHz spectrometer. The spectra were
acquired at room temperature (298K). The chemical shifts
are reported in ppm with respect to the references (external
tetramethylsilane (TMS) for 1Ha n d13C NMR). Elemental
analyses were carried out by the microanalytical service of
the University of Ioannina, Greece.
2.2. Synthesis
2.2.1. 3-Hydroxypyridine-2-carbaldehyde Semicarbazone
(1). Commercially available 3-hydroxy-(2-hydroxymethyl)
pyridine hydrochloride was oxidized with MnO2, prepared
by heating MnCO3 for 12h at 300◦C, according to [22, 23]
to aﬀord 3-hydroxypyridine-2-carbaldehyde as a yellow
powder, yield 62%, and m.p. 77◦C. The aldehyde (2mmol)
in EtOH (6mL) was then reacted with a solution of
semicarbazide hydrochloride (2mmol) in H2O( 3 m L )a t
80◦C for 2 h. Then, the mixture was kept in a refrigerator
overnight. The resulting yellow powder was ﬁltered oﬀ and
recrystallized from EtOH. The powder was washed with cold
EtOH and dried in vacuo over silica gel at 40–50◦Cf o r4ht o
aﬀord 1 as a yellow powder, yield 75%, and m.p. 230◦C. UV-
Vis for 1 (DMF) λ/nm (logε): 383 (2.78); 330sh (3.48); 320
(3.50). IRcm−1: 3275m, 3208m (ν(OH)); 3147s, 3080m,
2920 (ν(NH2, NH)); 1664 (ν(C=O)), 1583s (ν(C=N)); 1322
(ν(C–O)); 916s (ν(NN)). 1H-NMR (DMSO-d6): δ 12.36 (br,
NH), 11.23 (s, C3–OH), 8.05 (d, H4), 7.80 (t, H5), 8.35 (d,
H6), 8.14 (s, H7), 6.75 (br, NH2); 13C-NMR: δ 131.4 (C2),
154.0 (C3), 126.4 (C4), 126.4 (C5), 133.70 (C6), 134.7 (C7),
155.9 (C8=O). Anal. calc. for C7H8N4O2 (180.0gmol−1): C
46.7, H 4.5, N 31.10; found: C 46.6, H 4.3, N 31.3%.
2.2.2. [Ph2(HyFoSc)Sn] (2). Diphenyltin(IV) oxide (0.578g,
2.0mmol) and 3-hydroxypyridine-2-carbaldehyde semicar-
bazone (0.360g, 2.0mmol) in benzene (100mL) were
reﬂuxed for 24 h under azeotropic removal of H2O( D e a n -
Stark trap). The resulting clear solution was concentrated
in vacuo to a small volume. The oily product was chilled
and triturated with distilled diethyl ether (Et2O) to give
a yellow solid. The yellow powder was recrystallized from
distilled ether and was dried in vacuo over silica gel. Yield
24%; m.p. 209◦C. UV-Vis for 2 (DMF) λ/nm (logε): 388br
(3.87); 331sh (4.15); 320 (4.18). IRcm−1: 3144s, 3065m,
(ν(NH2)); 1664 (ν(C=O)), 1542s (ν(C=N)); 1283 (ν(C–O));
997s (ν(NN)) 339sh, 321ms (ν(SnC)); 446sh (ν(SnNC=N));
284mw (ν(SnOC=O)); 248mw (ν(SnO)). 1H-NMR (DMSO-
d6): δ 7.30 (d, H4), 7.36 (t, H5), 8.15 (d, H6), 8.20 (s, H7),
6.74(br,NH2),7.95(s,Ho),7.45,7.57(m,Hm,p). 13C-NMR:
δ 137.5 (C2), 153.2 (C3), 128.0 (C4), 128.2 (C5), 138.0 (C6),
139.5 (C7), 155.8 (C8=O), 134.7 (Co), 127.7 (Cm), 127.2
(Cp). Anal. calc. for C19H16N4O2Sn (451.0gmol−1) C, 50.6;
H, 3.6; N, 12.4; Found: C, 50.4; H, 3.7; N, 12.3%. Crystals
suitableforX-rayanalysiswereobtainedbyslowevaporation
of a freshly distilled diethyl ether solution of 2.
2.3. X-Ray Crystallography. Crystal data are given in Table 1,
togetherwithreﬁnementdetails.Allmeasurementswereper-
formedonaKumaKM4CCDkappa-axisdiﬀractometerwith
graphite-monochromated MoKα radiation (λ = 0.71073 ˚ A).
The data were corrected for Lorentz and polarization eﬀects.
An analytical absorption correction was applied to the data
using a multifaceted crystal model [24]. Data reduction
and analysis were carried out with the Kuma Diﬀraction
(Wroclaw) programs. The structure was solved by direct-
methods and reﬁned by a full-matrix least-squares method
onallF2 datausingtheSHELXL97[25].Nonhydrogenatoms
were reﬁned with anisotropic displacement parameters; all
hydrogen atoms were located from diﬀerent Fourier maps.
The C-bound H atoms were reﬁned with the riding model
approximation, while the N-bound H-atoms were freely
reﬁned isotropically. Molecular graphics were performed
with PLATON 2004 [26].
Crystallographic data for 2 have been deposited with the
CambridgeCrystallographicDataCentre,CCDC,634269for
compound 3. Copies of this information may be obtained
free of charge from The Director, CCDC, 12, Union Road,
Cambridge CB2 1EZ [FAX +44(1223)336-033] or e-mail
deposit@ccdc.cam.ac.uk or http://www.ccdc.cam.ac.uk.
2.4. Antiproliferative Assay In Vitro
Compounds. Test solutions of the tested compounds
(1mg/mL) were prepared by dissolving the substance in
100μL of DMSO completed with 900μLo ft i s s u ec u l t u r e
medium. Afterwards, the tested compounds were diluted
in culture medium to reach the ﬁnal concentrations of 100,
50, 10, 1, and 0.1ng/μL. The solvent (DMSO) in the highest
concentration used in the test did not reveal any cytotoxic
activity.
Cells. The cell lines are maintained in the Cell Culture
Collection of the University of Ioannina. Twenty-four hours
before addition of the tested agents, the cells were plated
in 96-well plates at a density of 104 cells per well. TheBioinorganic Chemistry and Applications 3
Table 1: X-ray crystal data and structure reﬁnement for 2.
Empirical formula C19H16N4O2Sn
Formula weight 451.05
Temperature (K) 100(2)
Crystal system Monoclinic
Space group P21/n
Crystal size (mm) 0.17 ×0.20 ×0.23
a(
  ˚ A) 10.5498(6)
b (
  ˚ A) 12.5794(7)
c(
  ˚ A) 13.9477(8)
β (◦) 103.594(5)
Volume (
  ˚ A3) 1799.2(2)
Z 4
Dcalcd (gcm−3) 1.665
Absorption coeﬃcient (mm−1) 1.441
θ range for data collection (◦) 3.0–36.6
Reﬂections collected 29597
Independent reﬂections (Rint) 8324 (0.056)
Data/parameters 8324/243
Goodness-of-Fit (F2) 0.857
Final R indices (I>2σ(I)) 0.037
wR 0.062
Maximum and minimum residuals (e·
  ˚ A−3) 1.03/−0.74
MCF-7 cells were cultured in the D-MEM (Modiﬁed Eagle’s
Medium) medium supplemented with 1% antibiotic and
10% fetal calf serum. L-929 cells were grown in Hepes-
buﬀered RPMI 1640 medium supplemented with 10%
fetal calf serum, penicillin (50U/mL), and streptomycin
(50mg/mL). A-549 cells were grown in F-12K Ham’s
medium supplemented with 1% glutamine, 1% antibi-
otic/antimycotic, 2% NaHCO3, and 10% fetal calf serum.
The cell cultures were maintained at 37◦Ci nah u m i da t m o -
sphere saturated with 5% CO2. Cell numbers were counted
bytheTrypanbluedyeexclusionmethod.MCF-7,L-929,and
A-549 cells were determined by the sulforhodamine B assay
[27], while T24 cells by the MTT assay [28].The in vitro tests
were performed as described previously [29].
3. Results andDiscussion
3.1. Synthesis. Compound 1 was synthesized by means of
the Heinert–Martell reaction (Scheme 1)[ 22]. The corre-
sponding diorganotin compound 2was prepared by reacting
diorganotin(IV) oxide with the semicarbazone in benzene
solution in a 1:1 molar ratio.
3.2. Crystal Structure of 2. Ap e r s p e c t i v ev i e wo f2, together
with the atom-labelling scheme, is given in Figure 1 and
selected bond lengths and angles are given in Table 2.
The doubly deprotonated ligand is coordinated to
the tin atom through the enolic-oxygen, azomethine-
nitrogen, and phenolic-oxygen atoms. Two carbon atoms
complete the ﬁvefold coordination at the diorganotin(IV)
fragment. Analysis of the shape determining angles using
the approach of Addison et al. [30] yields τ = 0.54 (τ
= 0.0 and 1.0 for SPY and TBPY geometries, resp.).
The metal coordination geometry is therefore described
as distorted trigonal bipyramidal with the O(2) and O(1)
atoms occupying the apical positions around the tin
atom.
The dianionic, tridentate ONO ligand has a ZEZ conﬁg-
uration, Figure 1. The coordinated part of the ligand is made
of three rings, two chelates Sn(1)O(2)N(1)N(2)C(4) (I) and
Sn(1)O(1)N(1)C(1)C(2)C(3) (II) and one heterocyclic ring
(III). The dihedral angles between the planes of the rings
I and II, I and III are 7.17(7) and 10.32(9), respectively,
indicating that the ligand as a whole deviates from planarity.
The C(3)–N(1) bond length is 1.298(3) ˚ A and is close to the
distance of a double bond (1.28 ˚ A). The deprotonation of
the N(2)H group produces a negative charge, which is delo-
calized in the C(3)–N(1)–N(2)–C(4) moiety. The distortion
from the ideal trigonal-bipyramidal conﬁguration is shown
by the O(1)–Sn(1)–O(2) angle of 156.78(6)◦,w h i c hd e v i a t e s
from the ideal value of 180◦, due in part to the ligand con-
straint. All the metal-donor bond distances, Table 2,a r es i m -
ilar to other organotin complexes presented in the literature
[18–21].
The polar hydrogen atoms on N(3) participate in two
intermolecular hydrogen bonds. The monomers of 2 are
connected into dimers by a pair of cooperative hydrogen
bonds [see Table 3 for geometric parameters describing these
interactions]. Further, adjacent dimers are connected by C–
H···N contacts, as illustrated in Figure 2.T h ep r e s e n c eo f
additional C–H→ π and π → π contacts further stabilizes
the crystal structure.
3.3. Spectroscopic Studies. In the IR spectrum of H2HyFoSc
(1), the strong bands at 3147 and 3088cm−1 are assigned
to the asymmetric and symmetric modes of terminal NH2,
respectively. The ν(NH) band appears at 2920cm−1.T h e
strong broad band at ca. 2650cm−1 is assigned to the
ν(NH···O) and ν(OH···O) mode due to strong intra-
or intermolecular hydrogen bonding. The absence of the
ν(NH) stretching motion at 2 is indicative of deprotonation
of the amide proton. The strong broad band at ca. 2650cm−1
at 2 is probably due to the ν(NH···N) intermolecular
hydrogen bonds as conﬁrmed by X-ray crystallography. The
coordination of the azomethine-N atom to the tin center
was suggested in the IR spectrum by a shift of the ν(C=N)
band to a lower frequency, along with the occurrence of a
ν(N–N) band to higher frequency [12, 13, 16]. An IR band
at 1322cm−1 for 1 was assigned to ν(C–O). This band was
found to be shifted to 1283–1289cm−1, in the spectrum of
2, which indicates the coordination of this O atom. The low
energy of the ν(C=O) vibration in the spectra of 1, that is,
1664cm−1, is indicative that the carbonyl O-atom is involved
in hydrogen bonding. The replacement of the hydrogen by
the metal atom does not shift this band to lower frequency.
Coordination of the imine nitrogen is also consistent with
the presence of a band at 446cm−1, assignable to ν(Sn–N).
Bands at 284 and 248cm−1 are assigned to ν(Sn–Oc=o)a n d
ν(Sn–Oc−o), respectively [18–21].4 Bioinorganic Chemistry and Applications
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Scheme 1: The reaction scheme for synthesis of 1 and2.
Table 2: Selected bond lengths (˚ A) and angles (◦)f o rc o m p l e x2.
Sn(1)–O(1) 2.073 (2) O(1)–Sn(1)–O(2) 156.78(6)
Sn(1)–O(2) 2.152(2) O(1)–Sn(1)–N(1) 84.71(6)
Sn(1)–N(1) 2.166(2) O(1)–Sn(1)–C(8) 98.51(7)
Sn(1)–C(8) 2.115(2) O(1)–Sn(1)–C(14) 95.64(7)
Sn(1)–C(14) 2.121(2) O(2)–Sn(1)–N(1) 73.14(6)
O(1)–C(1) 1.326(2) O(2)–Sn(1)–C(8) 95.84(7)
O(2)–C(4) 1.297(2) O(2)–Sn(1)–C(14) 91.13(7)
N(1)–N(2) 1.388(2) N(1)–Sn(1)–C(8) 110.80(7)
N(1)–C(3) 1.298(3) N(1)–Sn(1)–C(14) 123.88(7)
N(2)–C(4) 1.329(3) C(8)–Sn(1)–C(14) 124.44(8)
N(3)–C(4) 1.338(3) Sn(1)–O(1)–C(1) 132.5(2)
N(4)–C(2) 1.361(3) Sn(1)–O(2)–C4 113.6(2)
N(4)–C(7) 1.330(3) Sn(1)–N(1)–N(2) 116.2(2)
Table 3: Geometric parameters for hydrogen bonds and for C–H—π and π ···π interactions in 2.
DH A H ···AD ···A
N(3) –H(3A) ···N(4)(i) 2.29(2) 3.070(3) 175(3)
N(3) –H(3B) ···O(2)(ii) 2.07(3) 2.925(2) 183(4)
C(3) –H(3) ···N(2)(i) 2.34(2) 3.280(3) 170(3)
C(19) –H(19) ···O(2) 2.51(2) 3.087(3) 119
C–H(I)→Cg(J)(a) H–Cg C–Cg ∠C–H–Cg
C(7) –H(7)→Cg(5)(iii) 2.76 3.619(2) 151
C(12) –H(12)→Cg(5)(iv) 2.86 3.722(3) 152
Cg(I)→Cg(J)(a) Cg–Cg(b) β(c) CgI–Perp(d) CgJ–Perp(e)
Cg(3)→Cg(4)(v) 3.824(2) 10.55 3.7122(8) 3.759(2)
Cg(4)→Cg(3)(iv) 3.823(2) 10.55 3.759(2) 3.7121(8)
(a)Where Cg(3), Cg(4), and Cg(5) are referred to the centroids N(4)C(1)C(2)C(5)C(6)C(7), C(8)–C(14), and C(14)–C(19); (b)Cg–Cg is the distance between
ring centroids; symmetry transformations, (i) 2 − x,1− y, −z; (ii) 1 − x,1− y, −z; (iii) 1 + x, y, z;( i v )−1/2+x,1 /2 − y, −1/2+z;( v )1 /2+x,1 /2 − y,
1/2+z; (c)Where β is the angle Cg(I)→Cg(J) or Cg(i)→Me vector and normal to plane I (◦); (d)CgI–Perp is the perpendicular distance of Cg(I) on ring J;
(e)CgJ–Perp is the perpendicular distance of Cg(J) on ring I.Bioinorganic Chemistry and Applications 5
Table 4: The antiproliferative activity in vitro of H2HyFoSc and its organotin complex 2 (expressed as ID50 (μM)) against MCF-7, T-24,
A-549, and L-929 cancer cell lines.
Compounds L-929 A-549 T-24 MCF-7
[H2HyFoSc] (1) n.a 175.0 n.a. 164.0
[Ph2(HyFoSc)Sn] (2) 1.19 0.086 n.a. 8.65
[Ph2SnO] 10.73 47.10 n.a 3.46
Cisplatin 0.69 1.53 41.7 8.00
C(1)
C(2)
C(3)
C(4)
C(5)
C(6)
C(7)
C(8)
C(9)
C(10)
C(11)
C(12)
C(13)
C(14)
C(15)
C(16)
C(17)
C(18)
C(19)
N(3)
N(2)
N(4) N(1)
O(1)
O(2)
Sn(1)
Figure 1: Molecular structure of the diorganotin complex 2.
Thermal ellipsoids are drawn at the 40% probability level.
H(3)
H(3)
C(3)
N(4)
H(3A)
N(2)
N(3)
O(2)
N(4)
C(3)
N(3)
N(2)
H(3B)
H(3B) N(3)
O(2)
H(3A)
Figure 2: Arrangement of the intermolecular hydrogen bonds in 2.
Thermal ellipsoids are drawn at the 40% probability level.
1H- and 13C-NMR Spectra. In the 1H-NMR spectrum of 1,
the N(3)-H resonance at δ 12.30 and C–OH at δ 11.23ppm
indicates that these H atoms are involved in hydrogen
bonding,Figure 3.Inthe 1H-NMRspectrumof 2,theformyl
H-atom H–C(7) was shifted downﬁeld upon coordination,
which indicates variations in the electron density at position
7. Deshielding of carbons C4, C5, and C7 is observed in
complexes, which is related to the electrophilicity of the tin
atom. A σ-charge donation from the C–O and N donors to
the tin center removes electron density from the ligand and
produces this deshielding which will attenuate at positions
remote from the tin center, Figure 4.
N
OH
NN N H 2
H
C
O
1
2
3
4
5
6
7
8
NH H6
H7
H4
H5
11 10.51 09 .598 .58
ppm (t1)
(a)
C8C3
C6
C5
C4
C2,C7
155 150 145 140 135 130 125
ppm (t1)
(b)
Figure 3: 1HN M R( a )a n d13CN M R( b )s p e c t r u mo ft h el i g a n d
(1).
3.4. Pharmacology. Antiproliferative Activity In Vitro. Pd(II)
and Pt(II) complexes of 2-carbaldheyde thiosemicarbazone,
HFoTsc, were found to be active in vivo against leukemia
P388 cells and Pt(II) complexes of N4-ethyl 2-formyl and
2-acetylpyridine thiosemicarbazones showed cytotoxicity
and were found to be able to overcome the cisplatin-
resistance of A2780/Cp8 cells [10–16]. Also, Zn(II) com-
plexes of 2-carbaldheyde thiosemicarbazone, HFoTsc, and
2-acetylpyridiene thiosemicarbazone, HAcTsc, were found
activeagainsttheMCF-7(humanbreastcancercellline),T24
(bladder cancer cell line), and a mouse L-929 (a ﬁbroblast-
like cell line cloned from strain L) [29]. Compounds 1 and 2
and the organotin oxide precursor of 2 were tested for their
anti-proliferative activity in vitro against the cells of three
human cancer cell lines: MCF-7 (human breast cancer cell
line), T24 (bladder cancer cell line), A549 (non-small cell
lung carcinoma), and a mouse ﬁbroblast L-929 cell line [see
Table 4 for a summary of the cytotoxicity data].
The IC50 values for H2HyFoSc (1) against the MCF-7
and A-549 cell lines are 164 and 175μM, respectively, while6 Bioinorganic Chemistry and Applications
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Figure 4: 1HN M R( a )a n d13C NMR (b) spectrum of the complex
(2).
against the L-929 and T-24 cell lines IC50 are >555μM.
Thus, 1 is considered as nonactive against these tested cell
lines. Compound 2 is also considered nonactive against
T24 cell line. The IC50 values for 2 against the L-929 and
MCF-7 cell lines are 1.19 and 8.65μM, respectively. These
values are in the same range as observed for cisplatin and
Ph2SnO,indicatingthattheobservedcytotoxicityisprobably
due to the cytotoxicity of Ph2SnO. Compound 2 may then
be considered as a vehicle for activation of the Ph2SnO
as the cytotoxic agent. The IC50 value for 2 against A-
549 is 0.086μM and therefore 2 is signiﬁcantly more active
compared to Ph2SnO (47.1μM) and cisplatin (1.53μM),
respectively. Compound 2 is thus 547.7 and 17.8 times more
cytotoxicthanthePh2SnOandcisplatin, respectively,against
this cell line. Thus, 2 exhibits selectivity and is considered
as an agent with potential antitumor activity against A-549
tumor cell line and can therefore be a candidate for further
stages of screening in vitro and/or in vivo.
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